Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus EMVERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus EMVERM.
ANTEPAR vs EMVERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Category C
Category C
Anthelmintic
Anthelmintic